Translational vision science & technology · 2025
Improved IOL Power Calculation With Femtosecond Laser Enhanced Refractive Outcome Prediction.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Van Der Donckt Jeroen, Young Joshua A, Rademaker Michael, Menon Saurabh, Chang Chin-Wen, Vandewiele Gilles, Straker Benjamin, Dewey David, Dai George, Gonzalez Javier, Free Joseph R, Van Hoecke Sofie, Scott Wendell, Tauber Shachar, Dick H Burkhard, Scales Charles
Аннотация
PURPOSE: The purpose of this study was to introduce and evaluate the femtosecond laser enhanced refractive outcome (FLERO) prediction method, an intraocular lens (IOL) calculator that augments Barrett Universal II (BUII) by integrating novel anterior segment optical coherence tomography (OCT) biometric predictors obtained during femtosecond laser-assisted cataract surgery (FLACS).
METHODS: Two thousand, three hundred sixty-three (2363) eyes of 1720 patients (mean age = 71.33 years, 60.26% women) undergoing FLACS were analyzed. FLERO was developed by selecting the most predictive subset of OCT-derived biometry features using a "genetic algorithm" and combining them with BUII predictions in a linear model. Internal validation was performed through cross-validation, and prediction errors (PEs) were compared with BUII and Kane errors.
RESULTS: Compared to BUII, FLERO increased the proportion of eyes achieving postoperative refraction within ±0.25 diopter (D), ±0.50 D, and ±1.00 D of target from 0.470 to 0.507, 0.781 to 0.824, and 0.962 to 0.970, respectively. Mean absolute error decreased from 0.345 D for BUII and 0.338 D for Kane to 0.315 D for FLERO. FLERO outperformed BUII and Kane across (short, medium, and long) eyes, where proportions of eyes achieving refraction within ±0.50 D were 0.696, 0.831, and 0.782 for FLERO, 0.468, 0.796, and 0.718 for BUII, and 0.595, 0.798, and 0.718 for Kane. Wilcoxon Signed-Rank testing indicated significant reductions in absolute PEs for FLERO versus BUII and Kane (P < 0.0001). PE regression revealed FLERO made significantly smaller errors.
CONCLUSIONS: FLERO enhances BUII by incorporating novel OCT-derived FLACS biometric parameters across short, medium, and long eyes.
TRANSLATIONAL RELEVANCE: FLERO combines advanced FLACS-derived intraoperative biometry with established IOL formulae to refine refractive outcome prediction.
METHODS: Two thousand, three hundred sixty-three (2363) eyes of 1720 patients (mean age = 71.33 years, 60.26% women) undergoing FLACS were analyzed. FLERO was developed by selecting the most predictive subset of OCT-derived biometry features using a "genetic algorithm" and combining them with BUII predictions in a linear model. Internal validation was performed through cross-validation, and prediction errors (PEs) were compared with BUII and Kane errors.
RESULTS: Compared to BUII, FLERO increased the proportion of eyes achieving postoperative refraction within ±0.25 diopter (D), ±0.50 D, and ±1.00 D of target from 0.470 to 0.507, 0.781 to 0.824, and 0.962 to 0.970, respectively. Mean absolute error decreased from 0.345 D for BUII and 0.338 D for Kane to 0.315 D for FLERO. FLERO outperformed BUII and Kane across (short, medium, and long) eyes, where proportions of eyes achieving refraction within ±0.50 D were 0.696, 0.831, and 0.782 for FLERO, 0.468, 0.796, and 0.718 for BUII, and 0.595, 0.798, and 0.718 for Kane. Wilcoxon Signed-Rank testing indicated significant reductions in absolute PEs for FLERO versus BUII and Kane (P < 0.0001). PE regression revealed FLERO made significantly smaller errors.
CONCLUSIONS: FLERO enhances BUII by incorporating novel OCT-derived FLACS biometric parameters across short, medium, and long eyes.
TRANSLATIONAL RELEVANCE: FLERO combines advanced FLACS-derived intraoperative biometry with established IOL formulae to refine refractive outcome prediction.